Evaluation of combinational effect of Aprepitant and Dxamethasone on nausea and vomiting induced by high-emetic-risk chemotherapy in patients.

Evaluation of combinational effect of Aprepitant and Dxamethasone on nausea and vomiting induced by high-emetic-risk chemotherapy in patients. - PROEMEND

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010818

Enrollment

200

Registered

2013-05-28

Start date

2012-12-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient who has high-emetic-risk chemotherapy as first-ilne

Interventions

Group A: *1st course: Conventional therapy (Palonosetron 0.75mg i.v. on 1st day + Dexamathasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day) plus phosAprepitant (150mg i.v. on 1st day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who has high-emetic-risk chemotherapy as first line. (2)Performance Status (ECOG)=0-2

Exclusion criteria

Exclusion criteria: (1)Patients during pimozide administration (2)Patients who has severe liver failure or renal failure (3)Patients who enforced high- or moderate-emetic-risk chemotherapy in the past (4)Patients who has vomited or provoed nausea in the 24 hours prior to start of chemotherapy (5)Patients who is considered inappropriate as a target patient by a physician-in-charge

Design outcomes

Primary

Measure	Time frame
*Severity of nausea	—

Secondary

Measure	Time frame
Severity of nausea Grading of appetite Used amount of per-request medication weariness *hiccough	—

Countries

Japan

Contacts

Public ContactMasahiro Goto

Osaka Medical College Hospital Chemotherapy Cancter

in2030@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026